The first site for a new clinical trial run by Cleveland biopharmaceutical company Athersys Inc. (Nasdag: ATHX) is close to home.
Athersys announced in a news release early Friday morning, May 1, that University Hospitals Cleveland Medical Center is now open as the first clinical site for what the company calls the MACOVIA (MultiStem Administration for COVID-19 Induced Acute Respiratory Distress Syndrome) trial. MultiStem is a stem-cell therapy developed by Athersys.
Click here to read the complete story.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Originally published May 1, 2020.